Remove tag data-quality
article thumbnail

STAT+: The FDA has approved a new Alzheimer’s drug, but wide access may depend on CMS easing restrictions

STAT

Such decisions are based on myriad factors, starting with the average $26,500 price tag. But there are other considerations, including the quality of the clinical trial data, side effect concerns, the patient population for which the medicine is approved, and budgetary constraints.

FDA 96
article thumbnail

Smart pharmaceutical and healthcare labels: Lets trace medicines from its origin

Roots Analysis

It is worth noting that smart labels contain a transponder code which can be read by sophisticated devices, including radio frequency identification device (RFID) tags and near-field communication (NFC) chips. While most smartphones can read NFC chips, RFID tags can only be read by specialized receivers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Revolutionizing Medicine and Public Health: The Emergence of Big Data in Healthcare

Roots Analysis

Big Data in healthcare refers to the vast amount of data that is continuously expanding and cannot be efficiently stored or processed using traditional tools. Within the healthcare sector, structured data includes demographic details, vital indicators (like, height, weight, blood pressure, blood glucose).

article thumbnail

How automation can help to address supply chain challenges in pharma

pharmaphorum

Empowering labs with automated equipment that produces rich, traceable, and actionable data insights means pharmaceutical companies can ensure drug production runs smoothly – even under stress. Better communication with traceable data. Automation can be such a solution. Automation will be a large part of this long-term vision.

article thumbnail

Upcoming sickle cell gene therapies cost effective at $2 million, says ICER

Pharmaceutical Technology

Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. ICER uses quality-adjusted life year (QALY), a cost effectiveness metric to measure the value of a healthcare intervention.

FDA 59
article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Virtual connections. Do they have the right tone? Is there legacy branding? Personalising marketing content.

article thumbnail

ASH: Argenx cues up a second use for efgartigimod

pharmaphorum

Dutch biotech Argenx is on course to add another rare disease indication to the label of its FcRn blocker Vyvgart – primary immune thrombocytopenia (ITP) – thanks to new data reported at the ASH annual meeting.